Catalyst Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$4.4M
Doctors Paid
4,850
Transactions
16,481
2024 Total
$1.2M
Payment Breakdown by Category
Research$2.1M (48.4%)
Food & Beverage$402,682 (9.2%)
Consulting$231,253 (5.3%)
Travel$202,508 (4.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.1M | 176 | 48.4% |
| Honoraria | $1.3M | 542 | 29.3% |
| Food and Beverage | $402,682 | 14,111 | 9.2% |
| Consulting Fee | $231,253 | 91 | 5.3% |
| Travel and Lodging | $202,508 | 560 | 4.6% |
| Space rental or facility fees (teaching hospital only) | $73,600 | 13 | 1.7% |
| Grant | $36,250 | 11 | 0.8% |
| Education | $25,136 | 975 | 0.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,550 | 2 | 0.1% |
Payments by Type
General
$2.3M
16,305 transactions
Research
$2.1M
176 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| LONG TERM SAFETY STUDY OF AMIFAMPRIDINE PHOSPHATE IN PATIENTS WITH MUSK ANTIBODY POSITIVE AND ACHR (ACETYLCHOLINE RECEPTOR) ANTIBODY POSITIVE MYASTHENIA GRAVIS | $634,026 | 0 | 49 |
| A RANDOMIZED PLACEBO-CONTROL PARALLEL GROUP STUDY TO EVALUATE THE EFFECT OF AMIFAMPRIDINE PHOSPHATE IN PATIENTS WITH MUSK ANTIBODY POSITIVE MYASTHENIA GRAVIS AND A SAMPLE OF ACHR ANTIBODY POSITIVE MYASTHENIA GRAVIS PATIENTS | $406,791 | 0 | 26 |
| A RANDOMIZED, PLACEBO-CONTROL, PARALLEL GROUP STUDY TO EVALUATE THE EFFECT OF AMIFAMPRIDINE PHOSPHATE IN PATIENTS WITH MUSK ANTIBODY POSITIVE MYASTHENIA GRAVIS, AND A SAMPLE OF ACHR ANTIBODY POSITIVE MYASTHENIA GRAVIS PATIENTS | $340,072 | 0 | 19 |
| AN OPEN-LABEL EXPANDED ACCESS PROTOCOL FOR AMIFAMPRIDINE PHOSPHATE TREATMENT IN PATIENTS WITH CONGENITAL MYASTHENIA SYNDROME (CMS) LAMBERT EATON MYASTHENIA SYNDROME (LEMS) AND DOWNBEAT NYSTAGMUS | $307,789 | 0 | 44 |
| AMIFAMPRIDINE PHOSPHATE FOR THE TREATMENT OF CONGENITAL MYASTHENIC SYNDROMES | $167,829 | 0 | 7 |
| AN OPEN-LABEL, EXPANDED ACCESS PROTOCOL FOR AMIFAMPRIDINE PHOSPHATE TREATMENT IN PATIENTS WITH CONGENITAL MYASTHENIA SYNDROME (CMS), LAMBERT EATON MYASTHENIA SYNDROME (LEMS), AND DOWNBEAT NYSTAGMUS | $108,406 | 0 | 19 |
| EXPANDED ACCESS STUDY AMIFAMPRIDINE PHOSPHATE IN LAMBERT-EATON MYASTHENIC SYNDROME (LEMS),CONGENITAL MYASTHENIC SYNDROME | $60,541 | 0 | 3 |
| LONG TERM SAFETY STUDY OF AMIFAMPRIDINE PHOSPHATE IN PATIENTS WITH MUSK POSITIVE ANTIBODY POSITIVE MYASTHENIA GRAVIS PATIENTS | $28,349 | 0 | 4 |
| PROOF OF CONCEPT STUDY OF THE EFFECT OF AMIFAMPRIDINE (FIRDAPSE) ON NEUROMUSCULAR TRANSMISSION IN PATIENTS WITH ONABOTULINUMTOXIN A (BOTOX, BTX-A) | $18,500 | 0 | 1 |
| REGISTRY STUDY TO OBSERVE LONG-TERM SAFETY OF VAMOROLONE (AGAMREE) IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY | $16,193 | 0 | 1 |
| EFFECTIVENESS, TOLERABILITY AND LONG-TERM MAINTENANCE OF PERAMPANEL USED FOR STATUS EPILEPTICUS MANAGEMENT | $14,000 | 0 | 1 |
| REAL-WORLD SAFETY AND EFFICACY OF PERAMPANEL USE IN ELDERLY | $6,474 | 0 | 1 |
| STUDY TO EVALUATE AMIFAMPRIDINE PHOSPHATE IN PATIENTS WITH MUSK-MG | $5,698 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Cuixia Tian, M.d, M.D | Pediatrics | Cincinnati, OH | $13,245 | $0 |
| Dr. Seth Keller, M.d, M.D | Neurology | Lumberton, NJ | $12,936 | $0 |
| Leigh Maria Ramos-Platt, M.d, M.D | Pediatrics | Los Angeles, CA | $12,228 | $0 |
| Alicia Henriquez, Md, MD | Neurology with Special Qualifications in Child Neurology | Seattle, WA | $12,092 | $0 |
| Corey Langer, Md, MD | Internal Medicine | Philadelphia, PA | $12,082 | $0 |
| David Burdette, Md, MD | Epilepsy | Grand Rapids, MI | $12,002 | $0 |
| Dr. Anthony Geraci, M.d, M.D | Neurology | Great Neck, NY | $11,998 | $0 |
| Julio Cantero, Md, MD | Sleep Medicine | Sarasota, FL | $11,946 | $0 |
| Ms. Patricia Dean, Arnp, ARNP | Pediatrics | Miami, FL | $10,200 | $0 |
| Phu Truong, Md, MD | Hematology & Oncology | Wichita, KS | $9,937 | $0 |
| Julio Flamini, M.d, M.D | Neurology | Atlanta, GA | $9,930 | $0 |
| Dr. Michael Pulley, Md, MD | Neurology | Jacksonville, FL | $9,286 | $0 |
| James Valeriano, Md, MD | Neurology | Pittsburgh, PA | $9,145 | $0 |
| Srinivas Sadda, Md, MD | Ophthalmology | Pasadena, CA | $9,000 | $0 |
| Samir Macwan, M.d, M.D | Neurology | Rancho Mirage, CA | $8,860 | $0 |
| Dr. Perry Foreman, M.d, M.D | Neurology | Baltimore, MD | $8,842 | $0 |
| Dr. Ticiana Leal, M.d, M.D | Hospice and Palliative Medicine | Atlanta, GA | $8,803 | $0 |
| Trevor Resnick, Md, MD | Neurology with Special Qualifications in Child Neurology | Miami, FL | $8,296 | $0 |
| Nancy Kuntz, M.d, M.D | Neurology with Special Qualifications in Child Neurology | Chicago, IL | $7,819 | $0 |
| Omer Abdul Hamid | Neuromuscular Medicine | Orlando, FL | $7,640 | $0 |
| Sabrina Yum, Md, MD | Specialist | Philadelphia, PA | $7,559 | $0 |
| Vamshi Rao, Md, MD | Neurology with Special Qualifications in Child Neurology | Chicago, IL | $7,407 | $0 |
| Urvi Desai, Md, MD | Neuromuscular Medicine | Charlotte, NC | $7,397 | $0 |
| Dr. Jessica Nance, Md, MD | Neurology with Special Qualifications in Child Neurology | Baltimore, MD | $7,376 | $0 |
| Dr. Thomas Pitts, M.d, M.D | Neurology | New York, NY | $7,315 | $0 |
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. has made $4.4M in payments to 4,850 healthcare providers, recorded across 16,481 transactions in the CMS Open Payments database. In 2024, the company paid $1.2M. The top product by payment volume is FIRDAPSE ($2.9M).
Payments were distributed across 129 medical specialties. The top specialty by payment amount is Neurology ($946,310 to 2,001 doctors).
Payment categories include: Food & Beverage ($402,682), Consulting ($231,253), Research ($2.1M), Travel & Lodging ($202,508).
Catalyst Pharmaceuticals, Inc. is associated with 3 products in the CMS Open Payments database.